141 related articles for article (PubMed ID: 37978154)
1. Protein Disulfide Isomerase A2 Is Correlated with Immune Infiltrates and Is a Novel Prognostic Biomarker in Glioma Patients.
Ma ZG; Liu YX; Zou N; Huang Z; Wang M; Li T; Zhou J; Chen LG
Curr Med Sci; 2023 Dec; 43(6):1107-1115. PubMed ID: 37978154
[TBL] [Abstract][Full Text] [Related]
2. Protein Disulfide-Isomerase A3 Is a Robust Prognostic Biomarker for Cancers and Predicts the Immunotherapy Response Effectively.
Tu Z; Ouyang Q; Long X; Wu L; Li J; Zhu X; Huang K
Front Immunol; 2022; 13():837512. PubMed ID: 35401558
[TBL] [Abstract][Full Text] [Related]
3. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
Tian QS; Zhang Q; Huang W
Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
[TBL] [Abstract][Full Text] [Related]
4. N-linked glycosylation modulates dimerization of protein disulfide isomerase family A member 2 (PDIA2).
Walker AK; Soo KY; Levina V; Talbo GH; Atkin JD
FEBS J; 2013 Jan; 280(1):233-43. PubMed ID: 23167757
[TBL] [Abstract][Full Text] [Related]
5. Protein disulphide-isomerase A2 regulated intracellular tissue factor mobilisation in migrating human vascular smooth muscle cells.
Peña E; Arderiu G; Badimon L
Thromb Haemost; 2015 Apr; 113(4):891-902. PubMed ID: 25631539
[TBL] [Abstract][Full Text] [Related]
6. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
7. ABCD3 is a prognostic biomarker for glioma and associated with immune infiltration: A study based on oncolysis of gliomas.
Li J; Zhang Y; Qu Z; Ding R; Yin X
Front Cell Infect Microbiol; 2022; 12():956801. PubMed ID: 35959373
[TBL] [Abstract][Full Text] [Related]
8. P4HB and PDIA3 are associated with tumor progression and therapeutic outcome of diffuse gliomas.
Zou H; Wen C; Peng Z; Shao YΥ; Hu L; Li S; Li C; Zhou HH
Oncol Rep; 2018 Feb; 39(2):501-510. PubMed ID: 29207176
[TBL] [Abstract][Full Text] [Related]
9. Molecular and clinical features of a potential immunotherapy target ELK3 in glioma.
Xu H; Zhang L; Gao J; Wang J; Wang Y; Xiao D; Chai S
Medicine (Baltimore); 2022 Jul; 101(30):e29544. PubMed ID: 35905257
[TBL] [Abstract][Full Text] [Related]
10. SLC10A3 Is a Prognostic Biomarker and Involved in Immune Infiltration and Programmed Cell Death in Lower Grade Glioma.
Ma W; Mei P
World Neurosurg; 2023 Oct; 178():e595-e640. PubMed ID: 37543196
[TBL] [Abstract][Full Text] [Related]
11. Protein disulphide isomerase can predict the clinical prognostic value and contribute to malignant progression in gliomas.
Hu Q; Huang K; Tao C; Zhu X
J Cell Mol Med; 2020 May; 24(10):5888-5900. PubMed ID: 32301283
[TBL] [Abstract][Full Text] [Related]
12. Highly expressed of SERPINA3 indicated poor prognosis and involved in immune suppression in glioma.
Yuan Q; Wang SQ; Zhang GT; He J; Liu ZD; Wang MR; Cai HQ; Wan JH
Immun Inflamm Dis; 2021 Dec; 9(4):1618-1630. PubMed ID: 34449972
[TBL] [Abstract][Full Text] [Related]
13. Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma.
Xiulin J; Wang C; Guo J; Wang C; Pan C; Nie Z
Aging (Albany NY); 2022 Mar; 14(6):2819-2854. PubMed ID: 35349479
[TBL] [Abstract][Full Text] [Related]
14.
Qu S; Liu J; Wang H
Front Immunol; 2021; 12():648416. PubMed ID: 33889156
[TBL] [Abstract][Full Text] [Related]
15. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
Zhang J; Wang K; Hainisayimu T; Li H
Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
[TBL] [Abstract][Full Text] [Related]
16. Genetic Variants in Host Protein Disulfide Isomerase 2 (PDIA2) are Associated with Susceptibility to Chlamydia Trachomatis Infection.
Zysk C; Williams S; Chavarria I; Wilson H; Balogun A; Jacobs E; Kaminski R; Foma BT; Johnson J; Lux W; McCoy K; Morales S; Sanchez G; Grubb P; Littlejohn M; Mize R; Moreno J; Pirtle C; Hendrix EC; Bennett KM
J Assoc Genet Technol; 2020; 46(4):244-249. PubMed ID: 33293489
[TBL] [Abstract][Full Text] [Related]
17. [Bioinformatic analysis of the clinical significance of calneuron 1 (CALN1) in glioma and its correlation with immune cell infiltration].
Zhang H; Zhang J; Wang T
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Mar; 39(3):205-212. PubMed ID: 36946344
[TBL] [Abstract][Full Text] [Related]
18. High expression of PCOLCE gene indicate poor prognosis in patients and are associated with immune infiltration in glioma.
Guo Q; Gao X; Li J; Liu Y; Liu J; Yang H; Cui M; Zhang M; Duan L; Ma X
Sci Rep; 2023 Mar; 13(1):3820. PubMed ID: 36882457
[TBL] [Abstract][Full Text] [Related]
19. CLCF1 Is a Novel Potential Immune-Related Target With Predictive Value for Prognosis and Immunotherapy Response in Glioma.
Jiang Y; Ji Q; Long X; Wang P; Tu Z; Zhang X; Zhu X; Huang K; Li J
Front Immunol; 2022; 13():810832. PubMed ID: 35265072
[TBL] [Abstract][Full Text] [Related]
20. MELK is a prognostic biomarker and correlated with immune infiltration in glioma.
Yang H; Zhou H; Wang G; Tian L; Li H; Zhang Y; Xue X
Front Neurol; 2022; 13():977180. PubMed ID: 36353126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]